11/15
05:15 pm
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
High
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
11/15
04:59 pm
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
High
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
11/15
10:27 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/15
08:04 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
Medium
Report
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $16.00 price target on the stock.
11/15
08:04 am
annx
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Medium
Report
Annexon, Inc. (NASDAQ: ANNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/14
08:12 am
annx
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones [Yahoo! Finance]
Medium
Report
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones [Yahoo! Finance]
11/14
08:00 am
annx
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Medium
Report
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
11/13
04:22 pm
annx
Annexon Biosciences to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]
Low
Report
Annexon Biosciences to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]
11/13
04:05 pm
annx
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
Medium
Report
Annexon Biosciences to Present at the Jefferies London Healthcare Conference
10/21
08:15 pm
annx
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting [Yahoo! Finance]
Low
Report
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting [Yahoo! Finance]
10/21
08:00 pm
annx
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Low
Report
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
10/21
10:17 am
annx
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely [Yahoo! Finance]
Low
Report
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely [Yahoo! Finance]
10/16
08:00 am
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
10/15
08:00 am
annx
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
Low
Report
Annexon to Present New Phase 2 ARCHER Data for ANX007 in Dry AMD Patients with Less Advanced GA at the American Academy of Ophthalmology 2024 Meeting
9/16
08:00 am
annx
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
9/9
01:03 pm
annx
Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Annexon, Inc. (NASDAQ: ANNX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
9/9
08:00 am
annx
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
High
Report
Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in GA at the Retina Society 57th Annual Meeting and 24th Euretina Congress
9/3
08:00 am
annx
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
Medium
Report
Annexon Expands Senior Leadership in Commercial, Medical Affairs and Health Economics to Advance Global Late-Stage Neuroinflammatory-Targeted Portfolio
8/29
08:00 am
annx
Annexon Biosciences to Participate in Upcoming September Investor Conferences
Low
Report
Annexon Biosciences to Participate in Upcoming September Investor Conferences